
Triple agonist research peptide (GLP-1/GIP/glucagon).
Retatrutide is a next-generation synthetic triple-receptor agonist engineered to interact with GLP-1, GIP and glucagon receptors simultaneously. It has become a focal point of preclinical incretin research as scientists investigate multi-pathway metabolic signalling and energy homeostasis.
At NXT GEN PEPTIDES, our Retatrutide is manufactured to strict laboratory standards, characterised by HPLC and independently third-party tested. Each batch is lyophilised under sterile conditions and supplied in an amber vial to preserve peptide integrity throughout the research workflow.
Retatrutide is widely investigated in laboratory environments to explore areas including:
Scientific interest in triple-agonist peptides continues to expand as researchers characterise their molecular behaviour in controlled laboratory environments.
Every vial of Retatrutide supplied by NXT GEN PEPTIDES is carefully sourced, HPLC-characterised and independently third-party tested to help ensure purity, consistency and reliability. Our commitment to transparency and strict laboratory standards gives researchers confidence in every batch.
Store lyophilised at -20 °C. After reconstitution, store at 2–8 °C and use within 28 days.
This product is supplied exclusively for scientific and laboratory research. It is not intended for human or veterinary consumption, administration, diagnosis, treatment or therapeutic use.

Synthetic pentadecapeptide fragment for in-vitro laboratory characterisation.

Synthetic thymosin β4 fragment for in-vitro laboratory characterisation.

Copper tripeptide-1 for in-vitro biochemical characterisation.

Bundle: BPC-157 10 mg and TB-500 10 mg supplied together at a research-lab discount.